December 2013 in “Praxis medica” Using both DLQI and Skindex-16 together gives a better understanding of quality of life in skin disease patients.
September 2023 in “Journal of the American Academy of Dermatology” Methylprednisolone treatment helps most alopecia areata patients, but young age, extensive hair loss, and low vitamin D can affect results.
July 2024 in “LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)” Adipose tissue and eccrine gland displacement are common in certain alopecias but don't help differentiate between them.
January 2026 in “Journal of Cosmetic Dermatology” Topical 4-aminopyridine 5% does not improve hair growth in male pattern baldness.
1 citations
,
June 2020 in “Journal of AOAC INTERNATIONAL” Two new methods accurately measure Aminexil, Pyridoxine, and Niacinamide in hair products.
April 2026 in “Mendeley Data” April 2026 in “Mendeley Data”
5 citations
,
January 2018 in “Skin Research and Technology” TrichoScan needs optimization as it underestimated hair density by 38.9% compared to manual counting.
The combination therapy improved hair growth and thickness in people with androgenetic alopecia.
16 citations
,
February 2017 in “Dermatology and Therapy” The new visual scale is a quick and effective way to measure hair loss in women.
20 citations
,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Researchers created a fast, accurate computer program to measure hair loss in alopecia areata patients.
3 citations
,
November 2017 in “PubMed” Alopecia areata progression is linked to stress and hormone changes, suggesting new treatment targets.
1 citations
,
January 2014 The emulgel formulation F6 released more Minoxidil than the gel formulation F1.
3 citations
,
March 2024 in “Journal of the American Academy of Dermatology” Low-dose naltrexone helps improve symptoms and stabilize frontal fibrosing alopecia and lichen planopilaris.
4 citations
,
January 2019 in “Dermatology Online Journal” Low-dose naltrexone might be a cheap and effective additional treatment for hair loss with scalp discomfort due to its anti-inflammatory effects and few side effects.
November 2025 in “Archives of Dermatological Research” Using a higher concentration of triamcinolone acetonide leads to faster hair regrowth in scalp patchy alopecia areata.
August 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” Placebo effects in alopecia treatments are likely due to study design, not real improvement.
1 citations
,
January 2003 in “Dermatology” Finasteride's effectiveness measured by observing hair cortex changes using a cheap and easy method.
February 2020 in “Drug Analytical Research” Magistral pharmacies had issues with production quality and dosage accuracy.
1 citations
,
April 2020 in “Magnetic Resonance in Medical Sciences” MRI helps evaluate androgenetic alopecia severity.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
April 2023 in “Journal of Investigative Dermatology” Low-dose spironolactone effectively treats female pattern hair loss with mild side effects.
May 2025 in “Apollo Medicine” Trichoscopy is a useful tool for diagnosing and assessing the severity of alopecia areata.
December 2021 in “Benha Journal of Applied Sciences” Higher Alarin levels may predict androgenetic alopecia and metabolic syndrome.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
5 citations
,
February 2025 in “Journal of Clinical Medicine” A new method improves alopecia diagnosis using non-invasive steps.
3 citations
,
November 2020 in “Dermatologic Therapy” Start with 2.5 mg/mL triamcinolone acetonide for scalp alopecia areata and increase if needed.
7 citations
,
March 2025 in “Archives of Dermatological Research” Trichoscopy helps better understand and manage alopecia areata, improving patient outcomes.
November 2025 in “Figshare” Baseline severity, disease activity, and relapse history are key to predicting response and recurrence in alopecia areata.